Related references
Note: Only part of the references are listed.Combination Antifungal Therapy for Cryptococcal Meningitis
Jeremy N. Day et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Adjunctive interferon-γ immunotherapy for the treatment of HIV-associated cryptococcal meningitis: a randomized controlled trial
Joseph N. Jarvis et al.
AIDS (2012)
Comparison of the Early Fungicidal Activity of High-Dose Fluconazole, Voriconazole, and Flucytosine as Second-Line Drugs Given in Combination With Amphotericin B for the Treatment of HIV-Associated Cryptococcal Meningitis
Angela Loyse et al.
CLINICAL INFECTIOUS DISEASES (2012)
Combination Flucytosine and High-Dose Fluconazole Compared with Fluconazole Monotherapy for the Treatment of Cryptococcal Meningitis: A Randomized Trial in Malawi
Jesse C. Nussbaum et al.
CLINICAL INFECTIOUS DISEASES (2010)
Clinical Practice Guidelines for the Management of Cryptococcal Disease: 2010 Update by the Infectious Diseases Society of America
John R. Perfect et al.
CLINICAL INFECTIOUS DISEASES (2010)
Estimation of the current global burden of cryptococcal meningitis among persons living with HIV/AIDS
Benjamin J. Park et al.
AIDS (2009)
Independent Association between Rate of Clearance of Infection and Clinical Outcome of HIV-Associated Cryptococcal Meningitis: Analysis of a Combined Cohort of 262 Patients
Tihana Bicanic et al.
CLINICAL INFECTIOUS DISEASES (2009)
Screening for Cryptococcal Antigenemia in Patients Accessing an Antiretroviral Treatment Program in South Africa
Joseph N. Jarvis et al.
CLINICAL INFECTIOUS DISEASES (2009)
Reduced Neutrophil Count in People of African Descent Is Due To a Regulatory Variant in the Duffy Antigen Receptor for Chemokines Gene
David Reich et al.
PLOS GENETICS (2009)
Dose Response Effect of High-Dose Fluconazole for HIV-Associated Cryptococcal Meningitis in Southwestern Uganda
Nicky Longley et al.
CLINICAL INFECTIOUS DISEASES (2008)
High-dose amphotericin B with flucytosine for the treatment of cryptococcal meningitis in HIV-infected patients: A randomized trial
Tihana Bicanic et al.
CLINICAL INFECTIOUS DISEASES (2008)
Fluconazole alone or combined with flucytosine for the treatment of AIDS-associated cryptococcal meningitis
Eric Milefchik et al.
MEDICAL MYCOLOGY (2008)
Pharmacodynamic implications for use of antifungal agents
Russell E. Lewis
CURRENT OPINION IN PHARMACOLOGY (2007)
Oral versus intravenous flucytosine in patients with human immunodeficiency virus-associated cryptococcal meningitis
Annemarie E. Brouwer et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2007)
Determinants of disease presentation and outcome during cryptococcosis:: The CryptoA/D study
Francoise Dromer et al.
PLOS MEDICINE (2007)
Combination of amphotericin B with flucytosine is active in vitro against flucytosine-resistant isolates of Cryptococcus neoformans
Patrick Schwarz et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2007)
Outcome of AIDS-associated cryptococcal meningitis initially treated with 200 mg/day or 400 mg/day of fluconazole
C. F. Schaars et al.
BMC INFECTIOUS DISEASES (2006)
Results obtained with various antifungal susceptibility testing methods do not predict early clinical outcome in patients with cryptococcosis
E Dannaoui et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2006)
Efficacy of amphotericin B in combination with flucytosine against flucytosine-susceptible or flucytosine-resistant isolates of Cryptococcus neoformans during disseminated murine cryptococcosis
P Schwarz et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2006)
In vitro susceptibility of Cryptococcus neoformans clinical isolates from Egypt to seven antifungal drugs
HA Abdel-Salam
MYCOSES (2005)
Global trends in the antifungal susceptibility of Cryptococcus neoformans (1990 to 2004)
MA Pfaller et al.
JOURNAL OF CLINICAL MICROBIOLOGY (2005)
Antiretroviral roll-out, antifungal roll-back: access to treatment for cryptococcal meningitis
T Bicanic et al.
LANCET INFECTIOUS DISEASES (2005)
Decreased bioavailability of rifampin and other antituberculosis drugs in patients with advanced human immunodeficiency virus disease
P Gurumurthy et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2004)
In vitro activity of amphotericin B, fluconazole and voriconazole against 162 Cryptococcus neoformans isolates from Africa and Cambodia
J Chandenier et al.
EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES (2004)
In vitro interaction of flucytosine with conventional and new antifungals against Cryptococcus neoformans clinical isolates
P Schwarz et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2003)
Clinical pharmacology of antifungal compounds
AH Groll et al.
INFECTIOUS DISEASE CLINICS OF NORTH AMERICA (2003)
Comparison of three methods for in vitro susceptibility testing of Candida species with flucytosine
CB Moore et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2003)
An in vitro study on the active conversion of flucytosine to fluorouracil by microorganisms in the human intestinal microflora
A Vermes et al.
CHEMOTHERAPY (2003)
Clinical presentation, natural history, and cumulative death rates of 230 adults with primary cryptococcal meningitis in Zambian AIDS patients treated under local conditions
P Mwaba et al.
POSTGRADUATE MEDICAL JOURNAL (2001)
Trends in antifungal drug susceptibility of Cryptococcus neoformans isolates in the United States:: 1992 to 1994 and 1996 to 1998
ME Brandt et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2001)
Antifungal susceptibility testing: Practical aspects and current challenges
JH Rex et al.
CLINICAL MICROBIOLOGY REVIEWS (2001)
Antifungal susceptibilities, varieties, and electrophoretic karyotypes of clinical isolates of Cryptococcus neoformans from Brazil, Chile, and Venezuela
BM Calvo et al.
JOURNAL OF CLINICAL MICROBIOLOGY (2001)
Flucytosine: a review of its pharmacology, clinical indications, pharmacokinetics, toxicity and drug interactions
A Vermes et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2000)
In vivo characterization of the pharmacodynamics of flucytosine in a neutropenic murine disseminated candidiasis model
D Andes et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2000)
In vitro pharmacodynamic characteristics of flucytosine determined by time-kill methods
RE Lewis et al.
DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE (2000)
Share Paper
